Drug Abuse Science Gets Partial Public Peep Show
Published Date: 3/25/2025
Notice
Summary
The National Institute on Drug Abuse is holding a virtual meeting on May 13, 2025, to review grant applications and discuss important drug research topics. This meeting affects researchers and organizations seeking funding, with some parts open to the public and others private to protect sensitive info. No direct money changes are announced, but grant decisions could impact future funding.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
NIDA Will Review Grant Applications
On May 13, 2025, the National Advisory Council on Drug Abuse will meet virtually to review and evaluate grant applications (closed session 11:00 a.m. to 12:15 p.m.). This meeting directly concerns researchers and organizations that have submitted grant applications to the Institute.
Open Session Videocast for Public Viewing
The Council's open session on May 13, 2025, from 1:30 p.m. to 5:00 p.m. will be videocast and can be accessed from the NIH Videocasting and Podcasting website. Anyone may view the presentations and business of the Council via that videocast.
Portion Closed to Protect Confidential Information
A portion of the May 13, 2025 meeting (11:00 a.m. to 12:15 p.m.) will be closed to the public under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, commercial property, patentable material, and personal information tied to grant applications. That closed review applies to applicants whose materials could disclose confidential or personally sensitive information.
Anyone May File Written Comments
Any interested person may file written comments for the committee by emailing Dr. Gillian Acca; comments should include name, address, telephone number, and, when applicable, business or professional affiliation. The notice provides a clear, open channel for public input to the Council.
Accessibility Accommodations Available by Request
Individuals who plan to view the virtual meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Dr. Gillian Acca by email five days before the May 13, 2025 meeting. The Institute provides a process to request accommodations for the videocast.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06501 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.
2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration
The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!
2026-05957 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.
2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings
The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.
2026-05673 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)
The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!
Previous / Next Documents
Previous: 2025-04980 — National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a private virtual meeting on May 1, 2025, to review grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies. No public access or money changes are involved, but the review helps decide who gets research support.
Next: 2025-04982 — Certain Active Matrix Organic Light-Emitting Diode Display Panels and Modules for Mobile Devices, and Components Thereof; Notice of the Commission's Final Determination Finding No Violation of Section 337; Termination of the Investigation
The U.S. International Trade Commission looked into certain OLED display panels and parts used in mobile devices and found no rule-breaking. This means the investigation is over, and companies can keep making and selling these products without worry. No fines or penalties are coming, so business stays smooth and steady.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in